Filing Flows

Filing Flows › Companies › Jazz Pharmaceuticals › Cash flow

Jazz Pharmaceuticals cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow$490M in Q3 2026 · $1.6B over twelve months

Operating cash flow$506M
Capital spending−$16.2M
Free cash flow+$490M

Analysis

In Q3 2026, Jazz Pharmaceuticals generated $506M of operating cash flow and spent $16.2M on capital projects, leaving free cash flow of $490M. That is $30.4M more than in Q3 2025 ($460M).

Over the twelve months to Sep 30, 2026, operating cash flow was $1.7B; the largest uses were other financing ($1.0B), other investing ($907M), buybacks ($225M); besides operations, cash came from net borrowing (+) / repaid (−) ($1.2B), shares issued ($151M); the cash balance rose by $710M.

Operating cash flow was $506M against net income of −$483M. The largest differences: depreciation & amortization +$179M, stock-based pay +$77.2M, deferred taxes −$44.8M.

Free cash flow

Jazz Pharmaceuticals: free cash flow by quarterJazz Pharmaceuticals: free cash flow by quarter$385MQ4 2024$416MQ1 2025$75.9MQ2 2025$460MQ3 2025$346MQ4 2025$388MQ1 2026$398MQ2 2026$490MQ3 2026
Operating cash flow less capital spending.
Jazz Pharmaceuticals: operating cash flow against capital spendingJazz Pharmaceuticals: operating cash flow against capital spendingOperating cash flowCapital spending$399M$13.3MQ4 2024$430M$13.9MQ1 2025$88.8M$12.9MQ2 2025$475M$15.2MQ3 2025$362M$16.8MQ4 2025$408M$19.7MQ1 2026$416M$18.1MQ2 2026$506M$16.2MQ3 2026
Latest (Q3 2026): Operating cash flow $506M, Capital spending $16.2M.

Capital allocation, year by year

Jazz Pharmaceuticals: where the cash came from (up) and went (down), by fiscal yearJazz Pharmaceuticals: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingAcquisitionsBuybacksFY2021: Operating cash flow $779MFY2021: Net borrowing $369MFY2021: Shares issued $135MFY2021: Capital spending −$27.6MFY2021: Acquisitions −$6.2B$1.3BFY2021FY2022: Operating cash flow $1.3BFY2022: Net borrowing −$582MFY2022: Shares issued $98.0MFY2022: Asset sales $53.0MFY2022: Capital spending −$29.0MFY2022: Buybacks −$54K$1.4BFY2022FY2023: Operating cash flow $1.1BFY2023: Net borrowing −$31.4MFY2023: Shares issued $46.5MFY2023: Capital spending −$24.0MFY2023: Buybacks −$270M$1.1BFY2023FY2024: Operating cash flow $1.4BFY2024: Net borrowing $949MFY2024: Shares issued $20.6MFY2024: Capital spending −$38.1MFY2024: Buybacks −$311M$2.4BFY2024FY2025: Operating cash flow $1.4BFY2025: Net borrowing −$781MFY2025: Shares issued $108MFY2025: Capital spending −$58.8MFY2025: Buybacks −$125M$1.5BFY2025
Over these 5 years operating cash flow totalled $5.9B; the largest uses were acquisitions ($6.2B) and net borrowing ($1.4B). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$2.0B
Debt$5.6B
Net debt$3.5B
Due within a year$1.0B

Jazz Pharmaceuticals funds itself: free cash flow was $1.6B over the last twelve months, and $2.0B of cash and investments stands against $5.6B of debt ($1.0B due within a year, 2.0× covered by cash).

Jazz Pharmaceuticals: debt maturities by year (FY2025)Jazz Pharmaceuticals: debt maturities by year (FY2025)$1.0BYear 1$31.0MYear 2$1.8BYear 3$1.5BYear 4$1.0BYear 5
Principal due in each year as disclosed in the annual report, against $2.0B of cash and investments now.

Where the cash came from and went

Jazz Pharmaceuticals: sources (+) and uses (−) of cash, Q3 2026Jazz Pharmaceuticals: sources (+) and uses (−) of cash, Q3 2026Other financing$1.2BOther investing−$1.1BOperating cash flow$506MCash drawn (+) / kept (−)−$417MBuybacks−$225MCapital spending−$16.2MShares issued$10.6MNet borrowing (+) / repaid (−)−$7.8MTaxes on employees’ shares−$4.8MExchange rates$600K
Jazz Pharmaceuticals: sources (+) and uses (−) of cash, TTM to Q3 2026Jazz Pharmaceuticals: sources (+) and uses (−) of cash, TTM to Q3 2026Operating cash flow$1.7BNet borrowing (+) / repaid (−)$1.2BOther financing−$1.0BOther investing−$907MCash drawn (+) / kept (−)−$710MBuybacks−$225MShares issued$151MTaxes on employees’ shares−$120MCapital spending−$70.8MExchange rates−$345K

From profit to cash

Jazz Pharmaceuticals: net income to operating cash flow, Q3 2026Jazz Pharmaceuticals: net income to operating cash flow, Q3 2026Net income−$483MDepreciation & amortization$179MStock-based pay$77.2MDeferred taxes−$44.8MOther non-cash$100KReceivables$6.8MInventory−$15.6MPayables$1.7MAccrued liabilities−$14.4MPrepaid and other assets$19.3MOther liabilities$11.7MIncome taxes payable$3.2MOperating cash flow$506M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingBuybacksNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026$506M−$16.2M−$225M−$7.8M$10.6M−$417M$490M
Q2 2026$416M−$18.1M—−$7.7M$22.7M$224M$398M
Q1 2026$408M−$19.7M—−$7.8M$32.9M−$452M$388M
Q4 2025$362M−$16.8M−$23K−$7.7M$85.2M−$65.8M$346M
Q3 2025$475M−$15.2M—−$7.8M$700K−$136M$460M
Q2 2025$88.8M−$12.9M—−$7.7M$10.5M$672M$75.9M
Q1 2025$430M−$13.9M—−$758M$11.5M$551M$416M
Q4 2024$399M−$13.3M—−$7.8M$9.2M−$195M$385M

Jazz Pharmaceuticals: income statement and cash flow

Jazz Pharmaceuticals, Q3 2026: revenue $1.2B (+10% year over year), operating margin -33.3%. The chart follows the revenue to costs, profit and cash.

Jazz Pharmaceuticals: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.